Keyphrases
Overall Survival
85%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
74%
Chimeric Antigen Receptor T-cell Therapy
68%
Point-of-care
60%
Positron Emission Tomography-computed Tomography (PET-CT)
55%
Progression-free Survival
54%
Anti-CD19 chimeric Antigen Receptor T Cells
54%
Follicular Lymphoma
52%
Chimeric Antigen Receptor T Cells (CAR-T)
48%
FDG PET-CT
46%
Graft-versus-host Disease (GvHD)
46%
Complete Remission
45%
Large B-cell Lymphoma
44%
Oncology Patients
40%
Fluorine-18
40%
Israeli
40%
Fluorodeoxyglucose
40%
Immunoglobulin Genes
40%
Lymphoma Patients
35%
Cyclophosphamide
35%
Rituximab
35%
Retrospective Analysis
33%
Hematological Malignancies
33%
Salvage Therapy
31%
Disease Progression
31%
Confidence Interval
31%
Relapsed or Refractory
30%
Complete Response
30%
High Risk
30%
Genotype
30%
Hodgkin Lymphoma
28%
Adult Patients
27%
Treatment Failure
26%
Malignancy
26%
POD24
25%
Polymorphism
25%
COVID-19
25%
Clinical Outcomes
24%
Bendamustine
24%
Lineage Tree
23%
Leukemia Patients
23%
Clinical Characteristics
23%
B Cells
23%
Complementarity-determining Region 3 (CDR3)
21%
Tree-based Analysis
21%
Transplant Eligibility
20%
Allogeneic Transplantation
20%
Retrospective Review
20%
Neurolymphomatosis
20%
Advanced-stage Hodgkin Lymphoma
20%
Medicine and Dentistry
Positron Emission Tomography-Computed Tomography
100%
Overall Survival
93%
Large-Cell Lymphoma
70%
Progression Free Survival
68%
Chimeric Antigen Receptor T-Cell
67%
Chimeric Antigen Receptor T-Cell Immunotherapy
66%
Hodgkin's Lymphoma
60%
Follicular Lymphoma
58%
B Cell
50%
Non-Hodgkin Lymphoma
47%
Disease
45%
Salvage Therapy
44%
Fluorine-18
40%
Deoxyglucose
40%
Positron Emission Tomography
35%
Rituximab
35%
Cyclophosphamide
35%
Transplantation
25%
COVID-19
23%
Adriamycin Bleomycin Vinblastine Dacarbazine
23%
Allogeneic Stem Cell Transplantation
23%
Multiple Myeloma
20%
Cyclosporine
20%
Graft Versus Host Reaction
20%
COVID-19 Vaccine
20%
Epinephrine
20%
Cardiovascular Effect
20%
Lymphoma
20%
Humoral Immunity
20%
Quality of Life
20%
Meta-Analysis
20%
Bortezomib
20%
Gemcitabine
20%
Cancer
20%
BEACOPP
20%
Lymph Duct
20%
Chimeric Antigen Receptor T-Cell Therapy
20%
Conditioning
20%
Lidocaine
20%
Acute Lymphoblastic Leukemia
20%
Hematopoietic Stem Cell
20%
Fludarabine
20%
Case-Control Study
20%
Cell Transplantation
20%
Brentuximab Vedotin
20%
Thalidomide
20%
Chronic Lymphocytic Leukemia
20%
Precursor
20%
Dexamethasone
20%
Odds Ratio
20%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
76%
Follicular Lymphoma
60%
Hodgkin Disease
60%
Chimeric Antigen Receptor
60%
Disease
46%
Nonhodgkin Lymphoma
42%
Progression Free Survival
40%
Remission
36%
Cyclophosphamide
35%
Infection
27%
Chemotherapy
25%
Bendamustine
24%
Large Cell Lymphoma
24%
Actin
20%
COVID-19 Vaccine
20%
Epinephrine
20%
Fludarabine
20%
Graft Versus Host Reaction
20%
Acute Lymphoblastic Leukemia
20%
Bortezomib
20%
Ciclosporin
20%
Thalidomide
20%
Hematopoietic System Malignancy
20%
Lenalidomide
20%
Case-Control Study
20%
Syndrome
20%
Brentuximab Vedotin
20%
Vaccination Policy
20%
Dexamethasone
20%
Multiple Myeloma
20%
Articaine
20%
Nucleation
20%
Local Anesthetic Agent
20%
Gemcitabine
20%
Leukemia
20%
Lidocaine
20%
Fluorine 18
20%
Deoxyglucose
20%
B Cell Lymphoma
20%
Mantle Cell Lymphoma
20%
Myelodysplastic Syndrome
15%
Prednisone
15%
Rituximab
15%
Vincristine Sulfate
15%
Recurrent Disease
13%
Malignant Neoplasm
12%
Disease Exacerbation
10%
Disease Free Survival
10%
Clinical Trial
9%
Hematologic Malignancy
8%